Literature DB >> 23152502

The size and conservation of a coiled-coil structure in the ectodomain of human BST-2/tetherin is dispensable for inhibition of HIV-1 virion release.

Amy J Andrew1, Christopher E Berndsen, Sandra Kao, Klaus Strebel.   

Abstract

BST-2/CD317/tetherin is a host factor that inhibits HIV-1 release and is counteracted by HIV-1 Vpu. Structural studies indicate that the BST-2 ectodomain assumes a coiled-coil conformation. Here we studied the role of the BST-2 ectodomain for tethering function. First, we addressed the importance of the length and structure of the ectodomain by adding or substituting heterologous coiled-coil or non-coiled-coil sequences. We found that extending or replacing the BST-2 ectodomain using non-coiled-coil sequences resulted in loss of BST-2 function. Doubling the size of the BST-2 ectodomain by insertion of a heterologous coiled-coil motif or substituting the BST-2 coiled-coil domain with a heterologous coiled-coil motif maintained tethering function. Reductions in the size of the BST-2 coiled-coil domain were tolerated as well. In fact, deletion of the C-terminal half of the BST-2 ectodomain, including a series of seven consecutive heptad motifs did not abolish tethering function. However, slight changes in the positioning of deletions affecting the relative placing of charged or hydrophobic residues on the helix severely impacted the functional properties of BST-2. Overall, we conclude that the size of the BST-2 ectodomain is highly flexible and can be reduced or extended as long as the positioning of residues important for the stability of the dimer interface is maintained.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23152502      PMCID: PMC3531743          DOI: 10.1074/jbc.M112.418822

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Effects of side-chain characteristics on stability and oligomerization state of a de novo-designed model coiled-coil: 20 amino acid substitutions in position "d".

Authors:  B Tripet; K Wagschal; P Lavigne; C T Mant; R S Hodges
Journal:  J Mol Biol       Date:  2000-07-07       Impact factor: 5.469

2.  Increasing the precision of comparative models with YASARA NOVA--a self-parameterizing force field.

Authors:  Elmar Krieger; Günther Koraimann; Gert Vriend
Journal:  Proteins       Date:  2002-05-15

3.  A graphical interface for the FoldX forcefield.

Authors:  Joost Van Durme; Javier Delgado; Francois Stricher; Luis Serrano; Joost Schymkowitz; Frederic Rousseau
Journal:  Bioinformatics       Date:  2011-04-19       Impact factor: 6.937

4.  HIV-1 Vpu's lipid raft association is dispensable for counteraction of the particle release restriction imposed by CD317/Tetherin.

Authors:  Joëlle V Fritz; Nadine Tibroni; Oliver T Keppler; Oliver T Fackler
Journal:  Virology       Date:  2012-01-04       Impact factor: 3.616

5.  Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.

Authors:  Stuart J D Neil; Trinity Zang; Paul D Bieniasz
Journal:  Nature       Date:  2008-01-16       Impact factor: 49.962

6.  HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.

Authors:  Naoko Masuyama; Toshio Kuronita; Rika Tanaka; Tomonori Muto; Yuko Hirota; Azusa Takigawa; Hideaki Fujita; Yoshinori Aso; Jun Amano; Yoshitaka Tanaka
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

7.  A novel membrane antigen selectively expressed on terminally differentiated human B cells.

Authors:  T Goto; S J Kennel; M Abe; M Takishita; M Kosaka; A Solomon; S Saito
Journal:  Blood       Date:  1994-09-15       Impact factor: 22.113

8.  Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains.

Authors:  Daniel Sauter; Michael Schindler; Anke Specht; Wilmina N Landford; Jan Münch; Kyeong-Ae Kim; Jörg Votteler; Ulrich Schubert; Frederic Bibollet-Ruche; Brandon F Keele; Jun Takehisa; Yudelca Ogando; Christina Ochsenbauer; John C Kappes; Ahidjo Ayouba; Martine Peeters; Gerald H Learn; George Shaw; Paul M Sharp; Paul Bieniasz; Beatrice H Hahn; Theodora Hatziioannou; Frank Kirchhoff
Journal:  Cell Host Microbe       Date:  2009-11-19       Impact factor: 21.023

9.  A cytoplasmic tail determinant in HIV-1 Vpu mediates targeting of tetherin for endosomal degradation and counteracts interferon-induced restriction.

Authors:  Tonya Kueck; Stuart J D Neil
Journal:  PLoS Pathog       Date:  2012-03-29       Impact factor: 6.823

10.  Identification of Residues in the BST-2 TM Domain Important for Antagonism by HIV-1 Vpu Using a Gain-of-Function Approach.

Authors:  Takeshi Yoshida; Sandra Kao; Klaus Strebel
Journal:  Front Microbiol       Date:  2011-02-18       Impact factor: 5.640

View more
  11 in total

1.  Modulation of an ectodomain motif in the influenza A virus neuraminidase alters tetherin sensitivity and results in virus attenuation in vivo.

Authors:  Victor H Leyva-Grado; Rong Hai; Fiona Fernandes; Alan Belicha-Villanueva; Carol Carter; Mark A Yondola
Journal:  J Mol Biol       Date:  2013-12-29       Impact factor: 5.469

Review 2.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

3.  Activation of the ILT7 receptor and plasmacytoid dendritic cell responses are governed by structurally-distinct BST2 determinants.

Authors:  Mariana G Bego; Nolwenn Miguet; Alexandre Laliberté; Nicolas Aschman; Francine Gerard; Angelique A Merakos; Winfried Weissenhorn; Éric A Cohen
Journal:  J Biol Chem       Date:  2019-05-22       Impact factor: 5.157

4.  Positioning of cysteine residues within the N-terminal portion of the BST-2/tetherin ectodomain is important for functional dimerization of BST-2.

Authors:  Sarah Welbourn; Sandra Kao; Kelly E Du Pont; Amy J Andrew; Christopher E Berndsen; Klaus Strebel
Journal:  J Biol Chem       Date:  2014-12-18       Impact factor: 5.157

5.  Functional antagonism of rhesus macaque and chimpanzee BST-2 by HIV-1 Vpu is mediated by cytoplasmic domain interactions.

Authors:  Takeshi Yoshida; Yoshio Koyanagi; Klaus Strebel
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

6.  Vpu of a Simian Immunodeficiency Virus Isolated from Greater Spot-Nosed Monkey Antagonizes Human BST-2 via Two AxxxxxxxW Motifs.

Authors:  Weitong Yao; Takeshi Yoshida; Saki Hashimoto; Hiroaki Takeuchi; Klaus Strebel; Shoji Yamaoka
Journal:  J Virol       Date:  2020-01-06       Impact factor: 5.103

Review 7.  HIV accessory proteins versus host restriction factors.

Authors:  Klaus Strebel
Journal:  Curr Opin Virol       Date:  2013-11-15       Impact factor: 7.090

8.  Simian Immunodeficiency Virus SIVgsn-99CM71 Vpu Employs Different Amino Acids To Antagonize Human and Greater Spot-Nosed Monkey BST-2.

Authors:  Weitong Yao; Klaus Strebel; Shoji Yamaoka; Takeshi Yoshida
Journal:  J Virol       Date:  2021-12-08       Impact factor: 6.549

9.  Resilience of BST-2/Tetherin structure to single amino acid substitutions.

Authors:  Ian R Roy; Camden K Sutton; Christopher E Berndsen
Journal:  PeerJ       Date:  2019-05-31       Impact factor: 2.984

10.  Development and Characterization of the Shortest Anti-Adhesion Peptide Analogue of B49Mod1.

Authors:  Yuan Lyu; Wadie D Mahauad-Fernandez; Chioma M Okeoma
Journal:  Molecules       Date:  2020-03-06       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.